Skip to main content

NCT02295865 - A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis


CSR Summary

Not Yet Available


Data Specification

Available upon data access


Annotated CRF

Available upon data access

Product Info

Generic Name
Toreforant
Product Name
Therapeutic Area
Immune System Diseases
Enrollment
62
% Female
N/A
% White
N/A
Product Class
Histamine receptor antagonist
Sponsor Protocol Number
38518168PSO2001
Data Partner
Johnson & Johnson
Condition Studied
Psoriasis
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.